About Acarix

Innovative technology based on pioneering research

 

Acarix is a Scandinavia headquartered MedTech company marketing the CADScor®System – the innovative, non-invasive device designed to support a reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway.

Referring symptomatic patients to the right investigation method
Recent studies have shown that as few as 6-10% of patients referred to non-invasive testing suffer from significant CAD, meaning that nine out of ten patients should ideally be ruled-out from further investigations.1,2,3,4 With 96% confidence (negative predictive value), the CADScor®System has the potential to rule out up to 35% of the patients who experience symptoms such as chest pain, in a population with a 10.7% CAD prevalence. The diagnostic aid works as a support for decisions on how to continue the diagnostic pathway and reduce the number of referrals to costly investigations. The CADScor®System helps saving costs for the healthcare system5, while also avoiding long waiting times and unnecessary stress for the patient.

About Acarix

Acarix was established in 2009 as a spin-off from Coloplast A/S, a research and development collaboration based on pioneering research from the Aalborg University in Denmark. Since 2010, the Danish investors SEED Capital and Sunstone Life Science Ventures has supported Acarix towards its market introduction. After receiving the CE-mark, Acarix was listed on Nasdaq First North Premier in 2016. The first market introduction took place in Germany in 2017. In 2020 the CADScor®System was cleared by the FDA. Today, the CADScor®System is available in the Nordics, Germany, Austria, Switzerland, the UK, and the USA. 

“At Acarix, we are committed to making the rule-out of patients with symptoms of significant CAD easier, quicker and more reliable for all healthcare professionals.”

References
1. Therming, C. et al. Low Diagnostic Yield of Non-Invasive Testing in Patients with Suspected Coronary Artery Disease: Results From a Large Unselected Hospital-Based Sample. Eur Heart J – Qual Care Clin Outcomes 2018: 4, 301-308
2. Winther, S. et al. Diagnostic performance of an acoustic-based system for coronary artery disease risk stratification. Heart 2018: 104, 928-935.
3. Douglas PM et al. Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med 2015: 372, 1291-1300
4. Schmidt S et al. Coronary artery disease risk reclassification by a new acoustic‑based score. Int J Cardiovasc Imaging 2019: 35, 2019–2028.
5. Javanbakht M et al. Economic Analysis of the CADScor System for Ruling Out Coronary Artery Disease in England. PharmacoEconomics – Open (2021) doi.org/10.1007/s41669-021-00297-0